18264-Gall Bladder Cancer-NA-15

Gall Bladder Cancer

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number:

  • Address

880 W Central Rd, Suite 8200
Arlington Heights, IL 60005
P: (847) 259-4482

Search by practice name, trial titles, indicators and specific disease types.